46,873 Shares in Boston Scientific Co. (NYSE:BSX) Acquired by Quadrature Capital Ltd

Share on StockTwits

Quadrature Capital Ltd acquired a new position in Boston Scientific Co. (NYSE:BSX) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 46,873 shares of the medical equipment provider’s stock, valued at approximately $1,646,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BSX. Public Employees Retirement Association of Colorado boosted its holdings in Boston Scientific by 4.0% in the 1st quarter. Public Employees Retirement Association of Colorado now owns 265,058 shares of the medical equipment provider’s stock valued at $8,649,000 after purchasing an additional 10,265 shares during the period. Stratos Wealth Partners LTD. boosted its holdings in Boston Scientific by 5.3% in the 1st quarter. Stratos Wealth Partners LTD. now owns 6,975 shares of the medical equipment provider’s stock valued at $228,000 after purchasing an additional 351 shares during the period. Pendal Group Ltd boosted its holdings in Boston Scientific by 13.3% in the 1st quarter. Pendal Group Ltd now owns 12,438 shares of the medical equipment provider’s stock valued at $406,000 after purchasing an additional 1,463 shares during the period. Grimes & Company Inc. boosted its holdings in Boston Scientific by 4.7% in the 1st quarter. Grimes & Company Inc. now owns 21,362 shares of the medical equipment provider’s stock valued at $697,000 after purchasing an additional 963 shares during the period. Finally, State Board of Administration of Florida Retirement System boosted its holdings in Boston Scientific by 2.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 1,844,766 shares of the medical equipment provider’s stock valued at $60,195,000 after purchasing an additional 37,472 shares during the period. 90.24% of the stock is owned by institutional investors.

In related news, EVP Jeffrey B. Mirviss sold 60,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $40.93, for a total transaction of $2,455,800.00. Following the sale, the executive vice president now owns 115,622 shares of the company’s stock, valued at $4,732,408.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP David A. Pierce sold 2,170 shares of the business’s stock in a transaction dated Wednesday, July 22nd. The stock was sold at an average price of $38.00, for a total transaction of $82,460.00. Following the sale, the executive vice president now directly owns 9,401 shares in the company, valued at approximately $357,238. The disclosure for this sale can be found here. Insiders have sold a total of 112,755 shares of company stock worth $4,567,068 in the last ninety days. Insiders own 0.70% of the company’s stock.

Shares of BSX stock traded down $0.01 during mid-day trading on Friday, reaching $41.48. The stock had a trading volume of 9,232,429 shares, compared to its average volume of 6,781,371. The stock’s 50-day moving average price is $39.02 and its two-hundred day moving average price is $36.53. Boston Scientific Co. has a 52-week low of $24.10 and a 52-week high of $46.62. The firm has a market capitalization of $59.34 billion, a PE ratio of 14.71, a price-to-earnings-growth ratio of 4.29 and a beta of 0.95. The company has a current ratio of 1.87, a quick ratio of 1.38 and a debt-to-equity ratio of 0.59.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.12. Boston Scientific had a net margin of 39.18% and a return on equity of 12.86%. The firm had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.68 billion. During the same quarter in the previous year, the company earned $0.39 earnings per share. The company’s revenue for the quarter was down 23.9% compared to the same quarter last year. On average, equities research analysts forecast that Boston Scientific Co. will post 0.97 earnings per share for the current year.

BSX has been the subject of several analyst reports. Stifel Nicolaus raised their price target on shares of Boston Scientific from $45.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, July 30th. SVB Leerink lifted their price objective on shares of Boston Scientific from $40.00 to $43.00 and gave the stock a “market perform” rating in a report on Thursday, July 30th. Argus lifted their price objective on shares of Boston Scientific from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Oppenheimer lifted their price objective on shares of Boston Scientific from $41.00 to $43.00 and gave the stock a “market perform” rating in a report on Wednesday, July 29th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price objective on shares of Boston Scientific in a report on Wednesday, July 29th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the stock. Boston Scientific currently has a consensus rating of “Buy” and an average target price of $44.57.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.

See Also: Short Selling – Explanation For Shorting Stocks

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Co. (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply